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Cervical cytological examination is limited to inspection of cells, 
and the diagnosis of cervical intraepithelial neoplasia (CIN) requires 
the examination of cervical tissue to make a histological diagnosis. 
The risk of progression to cervical cancer is greatest for women with 
CIN III.[1]
One of the known predisposing causes for these preneoplastic 
changes is persistent infection with one or more of the human 
papillomavirus (HPV) types. The immune system’s inability to resist 
changes plays a vital role in the development of cervical carcinoma.[2] 
Immunocompromised individuals have an increased risk of cervical 
neoplasia.[3,4]
Globally, with an estimated 33 million people infected, the HIV/
AIDS pandemic is placing a huge burden on healthcare systems and 
has an enormous impact on women of all ages.[5,6] Approximately 
75% of women infected with HIV are living in sub-Saharan Africa, 
and South Africa (SA) has more HIV-infected women than any other 
country.[7,8]
It is well established that HIV-infected women have an increased 
susceptibility to HPV infections and HPV-associated lesions, which 
include CIN II/III and cervical cancer.[7,9-13] High-risk HPV (hrHPV) 
types and CIN are up to four times more common in HIV-positive 
women.[14] Even though HPV 16 and 18 are responsible for up to 
70% of cervical cancers, high-grade cervical lesions are more likely 
to be associated with non-HPV 16/18 types, especially among HIV-
infected women.[15,16]
In women with HIV coinfection, studies have shown that the 
chance of finding cervical HPV DNA together with abnormal 
cervical cytology increases as the CD4 cell count decreases.[17] A 
decline in CD4 cell count and rising HIV viral load are both risk 
factors for invasive cervical lesions.[6] However, some aspects of the 
relationship between CIN, immune depletion and the effect of highly 
active antiretroviral therapy (HAART) are not yet clear.[5]
Some data suggest that despite initiation of HAART and the 
associated CD4 cell count increase, most women will not experience 
regression of high-grade (CIN II/III) lesions.[18,19] It appears that 
immune status has a minimal role in either regression of high-grade 
lesions or cervical cancer advancing from these lesions. Although 
immune depletion results in an increased chance of premalignant 
cervical disease, it seems that other factors contribute to the 
development of cervical cancer from high-grade cervical lesions.[18,19]
Local data from Africa on the relationship between oncogenic 
HPV types, immune status and cervical preinvasive lesions are also 
incomplete.[20,21] The majority of studies reported in the literature 
used cytology results synonymously with cervical premalignant 
changes. [6,22] As cytology is only a screening test, it is important 
to compare the prevalence of oncogenic HPV types with 
histopathologically confirmed CIN in women with different levels of 
immune competence.
Methods
Study design
This was a descriptive study performed at the Gynaecological 
Oncology Unit at Steve Biko Academic Hospital and the University of 
Pretoria, SA. Data were obtained from 1 July 2010 to 30 August 2013. 
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Patients included in the study were women 
aged ≥18 years, referred for treatment of 
high-grade squamous intraepithelial lesions 
(HSILs) detected on conventional cervical 
cytological examination (Papanicolaou 
smears) as part of the national screening 
programme. The study population was 
representative of women attending public 
healthcare facilities in the Tshwane region.
Consent process and ethical 
considerations
Patients received counselling and an infor-
mation document that explained the method 
and voluntary nature of the study. During 
counselling by trained nursing personnel, 
patients were motivated to undergo HIV 
testing as per standard departmental 
manage ment protocols. It was clearly 
explained to them that testing was voluntary 
and not a prerequisite for treatment. Plan-
ned treatment was also explained: large 
loop excision of the transformation zone 
(LLETZ), or directed biopsies if malignancy 
was suspected. All patients were informed of 
their HIV results, if applicable. All patients 
tested for HIV received post-test counselling 
and were offered a CD4 cell count. These 
patients were referred to the appropriate 
antiretroviral therapy clinic for further 
management. This study was approved 
by the Research Ethics Committee of the 
Faculty of Health Sciences of the University 
of Pretoria (Refs 26/2010, 189/2012).
Patient recruitment
Three hundred and thirty-four consecutive 
patients referred with HSILs detected on 
cervical cytological examination were invi-
ted to participate in the study. Histological 
results were available for all patients. Only 
the 270 patients with confirmed CIN II or 
III were included in the final study analysis. 
Of the 64 patients excluded, 10 had cervical 
cancer, 25 had CIN I, 12 had cervicitis 
and 8 had no histological abnormalities. 
The specimens were inadequate for histo-
logical examination in 9 cases. The CD4 
cell count was recorded, if applicable, as 
was treatment with HAART. Based on 
the 2010 SA guidelines,[23] HAART was 
divided into different groups: patients not 
yet qualifying for HAART treatment (CD4 
count >350 cells/μL); patients in the process 
of initiating HAART (CD4 count ≤350 cells/
μL); and patients treated with HAART for 
<6 months, 6 - 12 months and >12 months.
Sample collection and transport
Patients underwent colposcopic evaluation 
and a LLETZ procedure or biopsy as indi-
cated. Samples were placed in buffered 
formalin and transported to the Department 
of Anatomical Pathology at the University 
of Pretoria, where histological examination 
was performed.
HPV testing, using a dry swab, was per-
formed on all participating patients. After 
collection, the swabs were transported in 
phosphate-buffered saline and 10% methanol 
solution to the Department of Medical 
Virology at the University of Pretoria, where 
HPV DNA testing was performed.
HPV DNA testing
DNA extraction was accomplished by 
means of the DNA Isolation Kit (Roche 
Molecular Systems, USA) on the MagNa 
Pure automated extraction system (Roche, 
USA). An HPV linear array genotyping 
kit (Roche Molecular Systems) was used to 
determine the HPV type. Fifteen high-risk 
types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73 and 82), three probable 
high-risk types (HPV 26, 53 and 66) and 
19 low/undetermined risk types (HPV 6, 
11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 
72, 81, 83, 84, IS39 and CP6108) were tested 
for.[24]
Data capturing and analysis
Data were captured on Excel datasheets 
(2011, Microsoft, USA), and analysis was 
performed using Stata statistical software 
release 11 (StataCorp, USA). Discrete data 
were mainly binary in nature and summary 
statistics were frequency, percentage, 95% 
confidence intervals (CIs), cross-tables 
and bar charts. Continuous data were 
summarised using descriptive statistics, 
means and standard deviations (SDs) along 
with 95% CIs. Comparison between groups 
was done with Fisher’s exact test for discrete 
outcomes and Student’s two-sample t-test or 
the Wilcoxon rank sum test for continuous 
outcomes. Testing was done at the 0.05 level 
of significance. Furthermore, the association 
between high-risk virus type and HAART 
use was assessed using logistic regression 
analysis and adjusted for age and CD4 cell 
count (logarithmic scale).
Results
The ages of the patients ranged from 21 to 
66 years. HIV results were available for all 
women. Of the 270 women, 225 (83.3%) 
were HIV-infected and 45 (16.7%) were not 
infected. There was no significant difference 
between the two groups with regard to age 
of diagnosis (p=0.186). CD4 cell counts 
were available for 205 of the 225 HIV-
infected patients (91.1%), and information 
on HAART treatment and duration was 
available for all (Fig. 1).
HPV prevalence
The prevalence of any HPV type in patients 
with CIN II/III was 96.7%, 97.8% among 
HIV-negative patients and 96.4% among 
HIV-positive patients. The prevalence of 
one or more hrHPV type/s was 93.0% in 
the entire population and 93.3% and 92.9% 
in HIV-negative and HIV-positive patients, 
respectively. Twenty-seven HIV-negative 
patients (60.0%) and 42 HIV-positive 
patients (18.7%) did not have any low-risk 
HPV (lrHPV) DNA detected.
Single and multiple hrHPV type 
infections
A total of 119 HPVs were detected in the 
45 HIV-non-infected patients, of which 82 
were hrHPV. The total number of HPV types 
detected in the 225 HIV-infected women 
was 1 090, with 577 of these categorised as 
hrHPV types. The number of HPV types 
detected per patient was significantly greater 
among HIV-infected v. non-infected patients 
for all HPV types (p<0.001) and for hrHPV 
types (p=0.014) (Fig. 1).
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Fig. 1. Descriptive statistics at baseline of the study population and average number of HPV infections 
per patient. 
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One-third (33.3%) of HIV-negative patients had a single HPV 
type infection, as opposed to only 18 HIV-positive patients (8.0%). 
Multiple HPV types were detected in 29 HIV-negative patients 
(64.4%) and 183 HIV-positive patients (81.3%). Three HIV-negative 
patients (6.7%) had no hrHPV infections, 20 (44.4%) were infected 
with a single hrHPV type, and the remaining patients (48.9%) had 
two or more hrHPV type infections. Forty-four patients (19.6%) 
coinfected with HIV had a single hrHPV type detected and 165 
(73.3%) had multiple hrHPV type infections.
HPV type distribution
In the group as a whole, the most prevalent hrHPV types, in 
descending order of frequency, were HPV 16, 58, 35, 52, 51 and 
45. The most prevalent hrHPV type in the HIV-negative group was 
HPV 16 (Fig. 2), followed by HPV 52, 31, 35, 58, 18, 33 and 45. 
HPV 84 was the most prevalent lrHPV type. In the HIV-infected 
group, HPV 16 was also the most prevalent hrHPV type, followed 
by HPV 58, 35, 51, 52, 45, 18 and 31. The most prevalent lrHPV 
type was HPV 62.
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Fig. 2. Distribution of hrHPV types among HIV-negative and positive patients with CIN II/III.
Table 1. hrHPV type distribution in relation to HAART treatment
HPV 
type
HIV– 
(N=45),
n (%)
No ARV 
(N=35),
n (%)
ARV >12 mo 
(N=43),
n (%)
ARV 6 - 12 
mo (N=37),
n (%)
ARV <6 mo 
(N=56),
n (%)
Start ARV 
(N=54),
n (%)
Total
(N=270),
n (%) p-value
16 14 (31.1) 15 (42.9) 11 (25.6) 7 (18.9) 22 (39.3) 19 (35.2) 88 (32.6) 0.206
18 5 (11.1) 5 (14.3) 7 (16.3) 3 (8.1) 11 (19.6) 11 (20.4) 42 (15.6) 0.570
31 8 (17.8) 5 (14.3) 3 (7.0) 7 (18.9) 11 (19.6) 8 (14.8) 42 (15.6) 0.562
33 5 (11.1) 4 (11.4) 10 (23.3) 7 (18.9) 6 (10.7) 7 (13.0) 39 (14.4) 0.494
35 8 (17.8) 5 (14.3) 10 (23.3) 12 (32.4) 15 (26.8) 15 (27.8) 65 (24.1) 0.434
39 2 (4.4) 3 (8.6) 4 (9.3) 7 (18.9) 8 (14.3) 7 (13.0) 31 (11.5) 0.384
45 4 (8.9) 5 (14.3) 9 (20.9) 6 (16.2) 11 (19.6) 10 (18.5) 45 (16.7) 0.659
51 5 (11.1) 7 (20.0) 8 (18.6) 8 (21.6) 15 (26.8) 14 (25.9) 57 (21.1) 0.433
52 10 (22.2) 9 (25.7) 9 (20.9) 11 (29.7) 12 (21.4) 7 (13.0) 58 (21.5) 0.492
56 2 (4.4) 2 (5.7) 6 (13.9) 5 (13.5) 8 (14.3) 8 (14.8) 31 (11.5) 0.412
58 8 (17.8) 8 (22.9) 8 (18.6) 16 (43.2) 15 (26.8) 13 (24.1) 68 (25.2) 0.141
59 1 (2.2) 5 (14.3) 2 (4.6) 7 (18.9) 4 (7.1) 6 (11.1) 25 (9.3) 0.092
68 3 (6.7) 2 (5.7) 3 (7.0) 4 (10.8) 4 (7.1) 7 (13.0) 23 (8.5) 0.826
73 3 (6.7) 1 (2.9) 2 (4.6) 4 (10.8) 11 (19.6) 6 (11.3) 27 (10.0) 0.111
82 4 (8.9) 2 (5.7) 5 (11.6) 2 (5.4) 1 (1.8) 4 (7.4) 18 (6.7) 0.451
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Association of hrHPV types  
with HAART use
The prevalence of hrHPV infections was 
lowest among patients who had been 
receiving HAART for >12 months. Except 
for patients who had been receiving HAART 
for between 6 and 12 months, HPV 16 was 
the most prevalent hrHPV type among all 
the different subgroups. Table 1 illustrates 
the distribution of the different hrHPV types 
in relation to HAART use.
Patients were divided into two groups. 
Firstly, patients not yet qualifying for 
HAART (CD4 count >350 cells/μL) and 
those who had been receiving HAART for 
≥12 months were grouped together. This 
group was compared with a second group 
comprising patients in the process of 
initiating HAART (CD4 count ≤350 cells/
μL) and patients who had been receiving 
HAART for <12 months. Adjusted for age 
and CD4 cell count on a logarithmic scale, 
the odds of being infected with HPV 18, 33, 
45, 51, 52, 59 and 82 were lower in patients 
not yet requiring HAART or on HAART 
for longer than 12 months (Table 2). There 
was a significant difference for HPV 33 
(p=0.029), 59 (p=0.009) and 82 (p=0.034) 
infections. The odds of having an HPV 73 
(p=0.004) infection were significantly lower 
in patients who had been receiving HAART 
for <12  months or were in the process of 
initiating HAART.
Vaccine-preventable infections
We investigated: (i) the prevalence of HPV 
16 and/or 18 infections alone, without any 
other hrHPV coinfections; (ii) only the rates 
of infection with the seven hrHPV types 
(HPV 16, 18, 31, 33, 45, 52 and 58) covered 
by the nine-valent vaccine; and (iii) rates of 
infection with other hrHPV types currently 
not specifically covered by vaccines.
As illustrated in Fig. 3, HPV 16 and/or 18 
were detected in 124 patients (45.9%) and 
214 (79.3%) were infected with HPV 16, 
18, 31, 33, 52 and/or 58. Only 37 patients 
(7.1%) were infected with hrHPV types not 
included in the nine-valent vaccine. The 
distribution of hrHPV types between HIV-
infected and non-infected patients was very 
similar.
Discussion
Background
The distribution of HPV types in this cohort 
of SA women with histologically confirmed 
CIN II/III is very important. In this study, 
the positive predictive value for CIN II or 
more severe changes for patients referred 
with cytological evidence of HSILs was 
83.6%. This highlights the importance of 
using histopathologically confirmed cervical 
lesions as the endpoint in the study of 
cervical disease.[25]
More than 80% of patients in this study 
were HIV-infected. Although not an AIDS-
defining disease like invasive cervical cancer, 
CIN is regarded as an HIV-related disease.[5] 
The HIV status of all patients was known, 
reflecting positively on a high uptake of 
voluntary HIV testing after appropriate 
counselling. Although premalignant lesions 
are more prevalent in HIV-infected women, 
because they come into contact with the 
health system relatively often, it is likely that 
they are better screened than women in the 
general population, which may explain the 
high rate of HIV infection in this study. The 
large percentage of patients infected with 
HIV also highlights the burden that the HIV/
AIDS pandemic places on SA’s healthcare 
system. Along with the risk of CIN among 
HIV-infected women, the risk of genital 
HIV shedding is significantly elevated in 
the presence of CIN, leading to an increased 
possibility of HIV transmission.[5]
HPV prevalence
The prevalence of any HPV in the current 
study was 96.7%. A recent meta-analysis 
reported the global prevalence of all HPV 
types in women with CIN II/III as ranging 
from 86% to 93%.[26] In 2012, the prevalence 
in Africa was reported as 89% for CIN II and 
83% for CIN III.[26]
The prevalence of one or more hrHPV 
types (93%) was similar to a Botswana study 
Table 2. Association of hrHPV types with HAART use adjusted for age and CD4 cell 
count for patients not requiring HAART or receiving HAART for ≥12 months
HPV type Crude OR Adjusted OR† 95% CI p-value
16 1.02 1.17 0.58 - 2.37 0.120
18 1.23 0.84 0.34 - 2.09 0.282
31 2.15 2.08 0.77 - 5.59 0.169
33 0.67 0.54 0.21 - 1.36 0.029*
35 1.44 1.23 0.57 - 2.65 0.551
39 1.75 1.87 0.68 - 5.12 0.639
45 0.95 0.78 0.34 - 1.83 0.685
51 1.35 0.93 0.42 - 2.05 0.164
52 0.66 0.98 0.43 - 2.22 0.132
56 1.42 1.24 0.47 - 3.28 0.739
58 1.51 1.43 0.65 - 3.17 0.146
59 1.13 0.93 0.30 - 2.84 0.009*
68 1.39 1.50 0.45 - 5.01 0.904
73 4.15 2.39 0.64 - 8.96 0.004*
82 0.49 0.23 0.06 - 0.86 0.034*
OR = odds ratio.
*Statistically significant.
†Adjusted for age and CD4 count on a logarithmic scale.
HIV-negative
HIV-positive
HPV
16, 18, 31, 33, 45, 52, 58
alone
HPV 16/18 alone Other hrHPV alone
Pa
tie
nt
s,
 %
90
80
70
60
50
40
30
20
10
0
42.2
46.7
77.8 79.6
15.6 13.3
Fig. 3. hrHPV type distribution of vaccine-preventable infections.
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(92%), but higher than prevalences reported from Kenya (82%) and 
SA (75%).[7,15,27] A study from Spain found an hrHPV prevalence of 
100% among 18 HIV-positive patients presenting with cytological 
evidence of HSILs.[10]
The prevalence of hrHPV was higher among patients with a CD4 
cell count <200 cells/µL (97.3%) than among patients with a CD4 cell 
count of ≥200 cells/µL (90.1%). This is considerably higher than the 
overall prevalence (84.1%) of HPV infections in HIV-positive women 
with HSILs reported by Clifford et al.[28]
Single and multiple HPV type infections
Compared with the HIV-negative cohort of patients in the study by 
McDonald et al.,[27] HIV-negative patients in this study had more 
multiple hrHPV type infections (49% v. 20%). Women infected 
with HIV are often coinfected with multiple types, as well as with a 
broader spectrum of HPV types.[16,29,30] There were more infections 
with multiple HPV types in this study than reported by Guan et al.[26] 
The 73.3% of HIV-positive patients coinfected with multiple hrHPV 
types represents a much higher proportion than reported in other 
studies (27.8 - 56%).[7,15,22]
Specific HPV types
In both the HIV-negative and HIV-positive groups, HPV 16 was 
the most prevalent hrHPV type, with almost one-third of patients 
infected. Disregarding HIV status, the most common hrHPV types 
identified were, in decreasing order of prevalence, HPV 16, 58, 
35, 52, 51, 45 and 31. This distribution differed from the meta-
analysis, compared with both global and African data, on HPV type 
distribution in patients with cytological evidence of HSILs published 
in 2006.[31] The most common types of hrHPV among patients with 
CIN II or CIN III, as illustrated by a more recent meta-analysis, were 
HPV 16 followed by HPV 52, 58, 31, 18, 33, 45 and 35.[26] There has 
been a worldwide increase in the prevalence of HPV 52 and 58 over 
the past 10 years.[15] Chen et al.[32] suggested that the long-term risk 
for developing cervical cancer was higher for HPV 58 than other 
non-HPV 16 types.
The just under 33% prevalence of HPV 16 in the entire study 
population is comparable to the prevalence reported by Guan et al.[26] 
for Africa (30.3%), which included both patients with CIN II/III and 
HSILs. The specific regions of Africa were not specified. The prevalence 
of just under 33% is also comparable to the global prevalence (34.7 - 
52%) reported by Clifford et al.[31] for patients with HSILs. However, 
the prevalence of HPV 16 (32.9%) among HIV-infected patients in 
this study is lower than in other reports on HIV-positive patients from 
Europe, SA and Botswana (37.5 - 45%), but also higher than reported 
in other African studies (26.5 - 29.4%)[7,10,15,21,30,33]
HPV and HAART use
Findings from a large review on the impact of HAART on HPV and 
CIN did not show a significant difference for women on HAART 
in relation to HPV and disease clearance. This study was limited 
by short follow-up periods of up to 24 months and did not account 
for treatment compliance.[34] More recent studies, however, have 
suggested that HrHPV infections can be cleared after a lengthy period 
of optimal HIV control and restoration of immune function. [35-38] The 
lower prevalence of HPV 16 among women treated with HAART for 
>6 months in this study may demonstrate a protective effect against 
new infections or improve clearance.
Study limitations
Limitations of the study include the fact that the patients who took 
part were from the referral areas served by Steve Biko Academic 
Hospital, so the findings cannot be extrapolated to the rest of SA. 
The small number of HIV-non-infected patients included is also a 
limitation. Although important information on hrHPV distribution 
among patients on HAART was obtained, little could be concluded 
regarding the effect of HAART-induced immune reconstitution on 
cervical lesion regression and persistent infections. A longitudinal 
study will be needed to evaluate this. This study also reported only on 
HPV DNA detected on the cervical surface and highlights the need 
to determine the specific HPV type or types incorporated within the 
specific lesion. Our unit is currently busy with a study comparing 
HPV types obtained from CIN lesions with surface HPV types.
Conclusion
In SA, burdened by the HIV pandemic, high numbers of high- and 
low-risk HPV type infections are present in women with cervical 
preneoplasia. The distribution of HPV types differs in HIV-infected 
patients. Administering the nine-valent HPV vaccine to women in 
our population may prevent as many as 80% of CIN II/III lesions. 
Not yet requiring HAART or having been receiving HAART for 
>12 months appear to be negatively associated with HPV 33, 59 and 
82, and positively associated with HPV 73. Knowledge about the 
specific HPV type distribution is crucial to direct development of 
future HPV vaccines and to guide HPV-based screening in both HIV-
infected and non-infected patients in this population.
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